Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer

Long, G. V.; Tykodi, S. S.; Schneider, J. G.; Garbe, C.; Gravis, G.; Rashford, M.; Agrawal, S.; Grigoryeva, E.; Bello, A.; Roy, A.; Rollin, L.; Zhao, X.

dc.contributor.author	Garbe, Claus
dc.date.accessioned	2019-07-10T06:43:28Z
dc.date.available	2019-07-10T06:43:28Z
dc.date.issued	2018
dc.identifier.issn	1569-8041
dc.identifier.uri	http://hdl.handle.net/10900/90201
dc.language.iso	en	de_DE
dc.publisher	Oxford Univ Press	de_DE
dc.relation.uri	http://dx.doi.org/10.1093/annonc/mdy408	de_DE
dc.subject.ddc	610	de_DE
dc.title	Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer	de_DE
dc.type	Article	de_DE
utue.quellen.id	20190321153956_00484
utue.publikation.seiten	2208-2213	de_DE
utue.personen.roh	Long, G. V.
utue.personen.roh	Tykodi, S. S.
utue.personen.roh	Schneider, J. G.
utue.personen.roh	Garbe, C.
utue.personen.roh	Gravis, G.
utue.personen.roh	Rashford, M.
utue.personen.roh	Agrawal, S.
utue.personen.roh	Grigoryeva, E.
utue.personen.roh	Bello, A.
utue.personen.roh	Roy, A.
utue.personen.roh	Rollin, L.
utue.personen.roh	Zhao, X.
dcterms.isPartOf.ZSTitelID	Annals of Oncology	de_DE
dcterms.isPartOf.ZS-Issue	11	de_DE
dcterms.isPartOf.ZS-Volume	29	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE